Cytta Corp. steht kurz vor dem breakout - 500 Beiträge pro Seite

[Toth]

cytta ist vor einiger zeit von 0,0005 auf 0,0035 gelaufen. dann ging es mit wenig volumen wieder down und sie hat bei 0,001 einen boden gefunden. die letzten tage ging es wieder aufwärts und bald sollte der widerstand bei 0,002 fallen. dann ist hier erhebliches kurspotential drin. charttechnisch sieht sie sehr bullish aus und bald sollte es hier news geben, dieses wurde von CEO schon angekündigt.




QUICK DD

Cytta Corp.
Symbol: CYCA
OTCBB

CHART


-----------------------------------------------------------------------------------------------------------------------------------------------
SHARE COUNT:

Shares Outstanding - CYCA 605 Million

661,400,000 shares of the issuer’s common stock.

56,000,000 common shares pending cancellation.
-----------------------------------------------------------------------------------------------------------------------------------------------

BOARD OF DIRECTORS

Stephen Spalding, MBA., B.Sc (Physics, Finance & Mathematics)
CEO, CFO, Director

Mr. Spalding brings more than 30 years of expertise in management as well as internal and external audit services, primarily related to internal controls, management structure and corporate governance in the investment banking, Hedge Fund, natural resources, manufacturing and technology industries. Stephen was a Senior Partner with Deloitte & Touché and also with KPMG for 11 years.



Colin Boog, B.Sc , Business
Director


Mr Boog a resident of The Hague, Netherlands, and the US, is seasoned in strategy development, business analysis, marketing and communications, he have earned an excellent reputation as a proven leader and manager with over 12 years of experience in strategic planning, IT project management, business development, leadership, marketing and communications management. He has a solid reputation for the delivery of innovative, effective and adaptive solutions using the latest leadership, proactive management and team communications techniques.

After working exclusively for over seven years in the timber, construction and green industries sector on a broad range of political, educational and communications related issues, he has expanded his consulting endeavours to include information technology, aerospace and the public sector. In the last five years, he completed a degree in Integrated Business Studies. His latest projects include strategic patent and corporate development in radio frequency identification (RFID), project communications and integration work for several government agencies and IT development for PARC Systems in the development and implementation of Information Management Systems.



Eric Smith, B.Sc , Business
Director
Eric has over 20 years of business management and consulting experience in various industries. Most recently, he has advised international organizations in the areas of enterprise risk management, corporate governance, and regulatory/legislative preparation (including Sarbanes Oxley). Eric held several global executive roles with Visa International over a ten-year period including CEO, Visa Human Resource Service (a Visa International subsidiary) and SVP, Head of Internal Audit.

-----------------------------------------------------------------------------------------------------------------------------------------------

CORPORATE STRATEGY

The primary markets for the are various vertical markets that require user-determined access technology. The company will be marketing the product into the vertical markets of medical, security, home technology systems, hospitality/gambling, banking/finance, and VOIP. The traditional horizontal markets such as the Telco’s, retail, multilevel and the Internet will be of secondary emphasis.


Prior to mass-market introduction, the Company seeks to identify dominant companies in each vertical market segment interested in introducing the Company's web screenphone to their specific market. Each of these Companies will utilize coordinated marketing programs to introduce the Company’s Web screen telephones within their chosen market segment.


By partnering with existing respected organizations in each of the vertical market segments, the Company will be able to ensure introduction to a very diverse segment of the public. This will also ensure that each of the distribution channels is evolving additional uses for our Company's product. The Company is focused on introducing the product to our partner’ specific vertical market segments and ensuring that their specific SASP is successfully developed for each configuration.

-----------------------------------------------------------------------------------------------------------------------------------------------

MEDICAL APPLICATIONS

There are numerous medical and home health care applications for the product. Health and medical information is one of the fastest growing areas of interest on the Internet and many companies involved in the healthcare industry are examining the use of the Internet as a mechanism for streamlining the provision of services in a secure manner. Our clients are examining uses in the following areas:


*
Home monitoring/patient evaluation
*
Testing and remote diagnostics
*
Education/communication/practice management
*
Eligibility/claims processing/billing
*
Medical records
*
Preions
*
Medical and other product sales
*
General interest and information


Now, medical practitioners can easily monitor and evaluate their patients by transmitting and receiving important diagnostic clinical data through a ScreenPhone to the Internet via the medical testing and evaluation portal, where patients can receive instant evaluation and professional interpretation of their results 24/7. Physicians will also receive notification of their patient's results via e-mail and may download the stored data from the portal or vertical partner’s portals at their convenience.

The primary benefits of the medical system are clinical, resulting in superior patient outcomes, psychosocial, resulting in better patient satisfaction, and economic, resulting in significantly lower costs.

The system provides solutions to the vexing problems plaguing healthcare providers and insurers by:

*
decreasing significantly the cost of quality healthcare
*
increasing the quality of healthcare, as evidenced by improved patient outcomes and better patient satisfaction
*
providing a simple and efficient mechanism by which physicians can monitor a large number of patients in a timely and cost efficient manner

[Toth]

rt chart

[Toth]

die letzte news (schon ein bisschen her)

Lifespan Licenses ScreenPhone Manufacturing Rights

Jul. 7, 2009 (U.S. Equity News) --

Lifespan (OTC: LSPN) (www.lifespaninc.com) (the "Company") has licensed Cytta Corp. (www.cytta.com) (OTCBB: CYTC) the exclusive right to utilize Lifespan's "ScreenPhone" technology to develop, manufacture and market telephone/internet access devices for the US. For these rights, Lifespan will receive six million shares of Cytta, a royalty of one-half of one percent (.5%) of Net Revenue and a cross obligation to purchase units at wholesale cost from 2010 on.

Mr. Ken Berscht, CEO, stated, "This transaction ensures that the ScreenPhone technology is developed, manufactured and brought to market in the most expeditious manner. It allows Lifespan to concentrate on the numerous and intricate developmental issues involved in completing the Medical ScreenPhone model, and the diverse elements involved in integrating and redesigning the medical peripherals."

Currently, administrative costs in the US Healthcare Industry exceed $200 billion each year. The Medical ScreenPhone can be utilized to significantly improve the efficiency of a portion of the US medical electronic data transfer (EDT) and electronic medical record (EMR) market. But the chief advantage of the Medical ScreenPhone is that it will ultimately improve the practice and delivery of healthcare to the benefit of doctors and their patients.

The Medical ScreenPhone is envisaged as a significant tool for the 14 trillion dollar US healthcare industry to utilize as a medical evaluation, testing, and diagnostic solution as well as a home healthcare communications and education tool. The Cytta transaction will now allow the Company to advance the involvement of Dr. Karim Quyami as Chief Scientist, and utilize his position as the Director of Centre of Excellence for Surgical Education and Innovation (CESEI, www.cesei.org) to begin development and redesign of the medical peripherals and actively pursue other industry partnerships focused solely on the medical peripherals.

To provide more complete financial disclosure, the Company has completed the management prepared Unaudited December 31, 2007 Annual Report; December 31, 2008 Annual Report; and March 31, 2008, June 30 2008, September 30, 2008 and March 31, 2009 Quarterly Reports. These documents are available for review on the Company's website at www.lifespaninc.com or directly at http://www.lifespaninc.com/joomla_22182/Financials.html. The Company is currently arranging for Auditor Review of these financials, which will enable the Company to update its financial disclosure reporting requirements.

Contact: Lifespan Inc. Ken Berscht, CEO, 403-830-7566 [e-mail] or Corporate Communications Stuart Brame, CIO, 310-963-0462 [e-mail] www.LifespanInc.com

Contact: U.S. Equity News Tel: [phone] Email: [e-mail]

Newstex ID: USE-1074-36300613

[lisa0099]

Antwort auf Beitrag Nr.: 38.185.643 von Toth am 15.10.09 16:31:29

Läuft der Zock jetzt an?????

Kamen mit einer PR nach Börsenschluss.

[lisa0099]

Antwort auf Beitrag Nr.: 39.182.792 von lisa0099 am 20.03.10 10:20:12

Tageschart

[lisa0099]

Antwort auf Beitrag Nr.: 39.182.795 von lisa0099 am 20.03.10 10:21:36

Ausbruch und keiner ist hier dabei

[longy3009]

warum ist hier ein Ausbruch? Geht es heute weiter?

[Kenai]

Leute kauft euch dieses Teil.
Es wir uns noch viel Freude machen.

[lisa0099]

Antwort auf Beitrag Nr.: 39.202.406 von longy3009 am 24.03.10 07:47:11

Die kommen von 0,0005 Us dollar.Liegen jetzt bei 0,003Us Dollar.Das nenne ich Ausbruch.

[Kenai]

Antwort auf Beitrag Nr.: 39.207.441 von lisa0099 am 24.03.10 16:53:04

Das ist noch nicht das Ende.
Wir werden noch viel höher kommen.

[lisa0099]

Antwort auf Beitrag Nr.: 39.202.406 von longy3009 am 24.03.10 07:47:11

0,005

[Kenai]

Antwort auf Beitrag Nr.: 39.209.135 von lisa0099 am 24.03.10 20:22:32

Moin
Was meint ihr geht es weiter up?

[mastika]

Antwort auf Beitrag Nr.: 39.210.539 von Kenai am 25.03.10 05:58:53

Servus
Glaubst du es könnte was werden?
Mal beobachten
Gruss mastika

[Kenai]

Antwort auf Beitrag Nr.: 39.216.983 von mastika am 25.03.10 18:56:20

Hy
Ja, denke hier hat man die Gelegenheit ein paar 100% zu machen.
Hast du schon zugeschlagen?

Gruß

[mastika]

Antwort auf Beitrag Nr.: 39.217.028 von Kenai am 25.03.10 19:01:30

Ich muss mich erstmal noch schlau machen , dann bin ich eventuell mit einer kleinen Posi dabei , der Reiz ist da!
Gruss

[Kenai]

Antwort auf Beitrag Nr.: 39.217.974 von mastika am 25.03.10 20:23:09

Mion
Mal schauen wie es heute läuft.

[mastika]

Antwort auf Beitrag Nr.: 39.221.230 von Kenai am 26.03.10 10:57:19

Sieht irgendwie nicht gut aus

[Kenai]

Antwort auf Beitrag Nr.: 39.221.291 von mastika am 26.03.10 11:03:49

Der Kurs in Berlin ist fürn Arsch.
Mal sehen wie es in den Staaten weitergeht.
Die Papiere sind seit heute gebucht.
Jetzt kanns UP gehen.

Gruß

[atomania]

Form 8-K for CYTTA CORP.

26-Mar-2010

Change in Directors or Principal Officers


ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
Effective on March 12th, 2010, Mr. Stephen Spalding CEO and Director has entered into an annual executive services contract with the Company under which Mr. Spalding will provide his management services to the Company in exchange for annual compensation of $60,000.

Following is a brief description of Mr. Spalding's business experience:

Stephen Spalding, age 60, is a senior corporate executive. Mr. Spalding is formerly a consultant with Grant Thorton. Mr. Spalding is also formerly CEO, Vigilant Privacy Corporation, a private Nevada corporation, from 2003 to 2008 where he procured the firms angel round of financing and lead the organization while the company's product was transformed from a desktop product to an enterprise security solution. Previously he was a Partner, Deloitte & Touche LLP, from 1997 - 2003, responsible for their IDI Practice (Implementation, Development and Integration) Division. He was formerly a partner at KPMG Peat Marwick LLP from 1995 - 1997, involved in Strategic Services, Enabling Technology Practice. Mr. Spalding is currently Assistant Professor, San Francisco State University, Business Systems Management and Control, Course Number 507 (Senior/Graduate Level), present. He has an MBA, in Quantitative Analysis, University of Arizona, 1974. He also has a B.S., Finance and Management, Eastern Illinois University, 1973, a B.S., Physics (solid state), Eastern Illinois University, 1969 and a B.S., Mathematics, Eastern Illinois University, 1969. Mr. Spalding resides in Mill Valley, California

Effective on March 12th, 2010 Mr. Gary Campbell was appointed President and Secretary to assist Mr. Stephen Spalding and also elected as a Director. The Company has negotiated a six month executive services contract under which Mr. Campbell will provide all usual management services to the Company for consideration of $30,000. There have been no transactions between Mr. Campbell and the Registrant during the prior fiscal year which would be required to be reported pursuant to Item 404(a) of Regulation S-K.

The following is a brief description of Mr. Campbell's business experience:

Mr. Campbell age 56, brings to the Company three decades of public company experience wherein he has assisted in the formation, operation and financing of several public companies and established ongoing contacts within the US and International technical, medical and financial community. In addition, Mr. Campbell was employed for many years as an attorney in the healthcare, mining and telecom sectors, where he oversaw a myriad of legal and business affairs. Mr. Campbell is currently the managing partner of Unified Financial Inc. a private organization that provides administrative services to public entities as well as advice on corporate reorganization and restructuring. Mr. Campbell has degrees in both Commerce and Law.

On March 19th, 2010 Mr. Karl Harz was appointed Vice President Business Development with a special mandate to focus upon the expansion and development of the Company's home healthcare model and technology. Mr. Harz was also elected

a member of the Board of Directors. The Company has negotiated a six month consulting contract with Mr. Harz in the amount of $30,000, whereby Mr. Harz will provide business development services. There have been no transactions between Mr. Harz and the Registrant during the prior fiscal year which would be required to be reported pursuant to Item 404(a) of Regulation S-K.

Following is a brief description of Mr. Harz's business experience:

Mr. Harz, 59, has an extensive background in sales, administration and finance including public company financing and administration, and conventional and private real estate funding. Mr. Harz has been passionately involved with the home healthcare industry and specifically the use of internet access devices to transmit and store medical information through home based peripherals for many years. Mr. Harz has previously been instrumental in the development and management of several major corporations including Transitional Housing Inc., a contract that was awarded through the Department of Justice: Province Service Corporation, a servicing arm of the mortgage companies; and presently, Alternative Funding Sources, Inc. Mr. Harz has managed and coordinated several major sales organizations with an emphasis on Real Estate properties, Trust Deed investments, Limited Partnership interests, and Public and Private Corporate Security products. Mr. Harz has maintained a California Real Estate Broker's License and has had a Series 22 and 63 licenses, a Life and Disability license and Variable Annuity License. He attended Farleigh Dickinson University in Teaneck, N.J., and graduated with a Bachelor of Science in Marketing and a Masters in Business Administration.

[Kenai]

Moin
War doch ganz vielversprechend der Verlauf von Gestern
Mal schauen wie es weiter geht.
Denke das wir in einer gesunden Aufwärtsbewegung sind.

Gruß

[mastika]

Antwort auf Beitrag Nr.: 39.243.169 von Kenai am 30.03.10 10:33:34

Ich glaub ich warte noch ein bisschen
Gruss mastika

[Kenai]

Antwort auf Beitrag Nr.: 39.246.439 von mastika am 30.03.10 16:09:13

Warte nicht zu lange.
Der Zug kann ganz schnell weg sein

Nicht das hier dann geweint wird

[mastika]

Antwort auf Beitrag Nr.: 39.248.314 von Kenai am 30.03.10 19:00:03

Wenn du wüsstest wie oft ich schon geweint habe , ob einmal mehr oder weniger is aach wurscht
MfG mastika

[Kenai]

Heute gehts wieder up

wir werden noch viel spaß hier haben

[Kenai]

Na wer sagst denn
solche tage werden wir noch öfters sehen.

[Kenai]

moin

mal schauen wo die reise in den nächsten wochen hingeht.

hat jemand infos?

[Kenai]

Mal schauen wie es weiter geht.
konnte leider keine news finden.

sollten heute aber anschlusskäufe kommen.

nice day

[Kosar31]

Antwort auf Beitrag Nr.: 39.466.416 von Kenai am 06.05.10 09:25:32

SOURCE: Cytta Corp.

May 05, 2010 09:30 ET
Cytta Stitching Together e-Health Model With Additional Medical Expertise

SAN FRANCISCO, CA--(Marketwire - May 5, 2010) - Cytta Corp's (OTCBB: CYCA) CEO Mr. Stephen Spalding wishes to announce that Cytta is diligently continuing its discussions with several innovative technical and software-based organizations working to develop and implement the various elements which go into the current e-Health strategy as well as negotiations with providers interested in utilizing the model being embraced by the Company.

To aid the Company in it sobjectives it is pleased to announce that Dr. William Blase is also adding his considerable expertise to the Cytta Project by joining the Board of Advisors. Dr. Blase has had a distinguished career in all aspects of the medical profession, with a practice emphasis on Ophthalmology, a background in medical research, as well as administration and management issues of modern medical practice.

Dr. Blase has envisioned and actively worked to develop and introduce a comprehensive home-based healthcare system for the past decade. Dr. Blase will be focusing on assisting the Company with selecting and developing technologies that have the potential to move healthcare to a more proactive, consumer-centric model of care, capable of improving the cost, quality, and accessibility of healthcare services utilizing the full range of technologies accessible to the market.

Dr. Blase was also pleased to note that the new Patient Protection and Affordable Care Act (PPACA) and the effect e-Health could play was subject of the Senate Committee on Aging last week which examined some of the potential benefits of the Act on distribution of healthcare, and examined how Americans will interact with doctors and other health care providers utilizing e-Health.

The effort, loosely called e-Health or e-Care, combines leading edge healthcare technology with 21st-century Internet and other connectivity. It will allow doctors to interact with their patients through innovations such as video monitoring, cellular or internet checkups, and home-health monitoring devices that relay data over cellular or wireless Internet connections. The realization that e-Health will allow significant improvements in outcomes while reducing overall costs is truly encouraging

Dr. Blase has over the years been involved in several technology ventures, most with an emphasis on improving the dissemination of medical information or utilizing Internet technology to improve the delivery of medical services. Dr Blase's experience and skill in dealing with the multitude of private, state and federal medical administrative/service organizations, insurance companies and drug companies will be of enormous value as the Cytta project proceeds.

Dr. Blase is formerly the Chairman of the Department of Ophthalmology at the Hemet Valley Hospital and a Director of California Eye Care. Dr. Blase was also a Trustee for a California District Hospital System. Dr Blase has also served eight years as a Trustee of the Valley Health System in Riverside California and was formerly the Chairman of the Board, as well as a Trustee of the Employee Health, Pension, and Retirement Funds

Dr. Blase is also a Diplomate of the National Board of Medical Examiners, the American Board of Ophthalmology, and has published numerous articles and several book chapters. Dr. Blase is a graduate of Dartmouth College, the University of Virginia School of Medicine and Oxford University, and did his medical post graduate training at Johns Hopkins in Baltimore MD.

Contact:
Cytta Corp.
Corporate Communications
Karl Harz: 213 841 0094
[e-mail]
website: Cytta.com
Click here to see all recent news from this company

[Walfaenger]

..seit gestern ist die webseite wenigstens mal wieder online..vielleicht geht ja bald mal was..

[Saftladen]

[Walfaenger]

CYCA- schließt gestern auf TH, mal schauen was die woche noch so bringen kann..

[Nikkitawin]

Ich update mal diese Forenleiche:

CYCA könnte in kürze losgehen, Grund ist folgende
PR, zu der ich wichtige Updates erwarte und die Akkumulation ist
ebenfalls eindeutig:

Date : 01/07/2013 @ 9:30AM
Cytta Completes Mobile Monitoring Technology Pilot Program and Begins Licensing Discussions

The President of Cytta Corp. (OTCBB: CYCA) (OTCQB: CYCA), manufacturer of the CyttaConnect Open Source mobile monitoring technology, has issued the following update outlining the Company's future plans in anticipation of their upcoming licensing meetings at CES this week.

Cytta Corp. has successfully completed the design, development and now full scale trial implementation of the world's first open source special purpose cellular network. Cytta Connect's first Trial makes available a plethora of exciting, yet affordable and easy-to-use Bluetooth based medical/health/wellness testing products and services, which connect through our open source smartphones. Our smartphones allow people and their physicians to monitor their personal health, wellness and fitness in addition to all normal smartphone functionality.

Additionally, while we designed our technology for the exceptionally high standards of the medical industry, our open source mobile network is 'any Bluetooth device friendly.' Our network allows us to connect any data generating devices via Bluetooth through our proprietarily programmed smartphones and deliver that data in real time to a web based interface and then back to the smartphone.

We formed the Company with the idea of revolutionizing the home based medical testing sector and then we created a new form of mobile network designed to move generated data seamlessly.

We commissioned Connected Health Pte. Ltd., to create a mobile phone based monitoring technology. They developed a proprietary technology utilizing the native programing in our cell phones, which we call the "Super App." This technology allows our cell phones to seamlessly connect with Bluetooth medical and other testing devices and automatically forward that data to our cloud based database and downstream users.

The Super App technology required that we obtain access to a US Mobile Network and obtain authorization to alter native phone programming and create a proprietary special purpose network. We partnered with Vonify Inc. for a full MVNO (Mobile Virtual Network Operator) status and assisted with the integration of the Super App with their US cellular network. Months of arduous testing involving all elements of the solution including voice, data and SMS have resulted in an integrated network capability that exceeds any other alternative. Additionally, we have now secured and fully implemented a US and International Data MVNO from AT&T which provides us with backup and additional network opportunities.

Moving medical data that could be directly 'utilized' by medical professionals required the use of high quality FDA approved Bluetooth medical testing devices. We were able to automatically utilize our Super App to integrate into our Bluetooth ecosystem, the A&D Medical scale, the A&D Medical blood pressure device, the Nonin Medical Inc. pulse oximetry device and the "MyGlucoHealth" diabetes meter from Entra Health Systems. However the Cytta Connect network and smartphones can easily interface with any information generating Bluetooth device.

We created an internet or Cloud based Electronic Relational Database to act as a Medical Record for the data from our devices to populate, since there was no precedent for the real time medical database the medical devices were now generating. The Cytta Dashboard or Instant EMR is automatically populated with the patient's data and provides an interactive and interpretive interface for review by the patient's providers and caregivers. The data can be displayed in various numerical formats, it can be graphed to show trends of these measurements and it may be utilized to provide early warning signs of dangerous health trends. The Dashboard can also be used to monitor and issue warnings for any type of data being generated. Licensing discussions in the Oil and Gas, Transportation, Security and other industries are ongoing.

Having 'premiered' our technology in the medical monitoring industry, we needed a medical technical organization to be responsible for the servicing of the high end medical testing units being deployed in our Field Trial. We worked with Medi-Home Individualized Monitoring Systems Corp. (MHIMS) who helped design the Trial and then implemented the ecosystem of devices to be utilized by the patients to provide meaningful and timely information to their caregivers in real time.

We established our initial Pilot Program installation with the Heritage Provider Network (HPN) Regal /Lakeside Medical Group, under the auspices of Dr. Terry Olson. HPN is a large full risk, capitated medical group located in Southern California. Under the terms of the Trial they completed a 90 day and more recently a 120 day Pilot Study to determine, 'if high cost patients, not well managed in traditional care coordination programs and traditional healthcare delivery systems, can decrease cost of care and improve patient satisfaction, through remote telemonitoring using the CYTTA Connect Ecosystem and an intense case management process.'

Patient satisfaction and costs reductions were then measured. MHIMS provided assistance and advice in conjunction with Dr. Terry Olson's team. Cytta is delighted with the results MHIMS and Dr. Olson have achieved with our technology in the medical monitoring field. Their results are set out in the 6 month Pilot Study Whitepaper by Dr. Olson titled "Biometric remote telemonitoring to produce a healthy return on investment, decrease resource utilization, and improve care coordination" is attached as Appendix A. Also available on request is our Cytta Technical Whitepaper summarizing the technical aspects of the Trial.

Excerpts from Dr. Olson's Independent Report summarize the Cytta Technology Pilot Program as follows,

"This trial demonstrated the ability to significantly reduce costs for high risk patients through use of the CYTTA Connect Ecosystem. The trial demonstrated the ability to quickly achieve cost savings, decrease resource utilization, improve care coordination, and increase adherence to evidence based guidelines."

"Care costs were reduced on average by $11,078 for each trial participant through the trial [or $1,846 per member per month]. This trial did not specifically address long term cost of care. However, these patients were selected for the inabilities of the existing healthcare system and care coordination programs to cost effectively address their short or long term healthcare needs. One trial participant noted he realized more value and benefit in 2 months of trial participation compared to his previous 17 months of participation in the best available care coordination services."

"This trial discovered patients view CYTTA Connect and remote telemonitoring as a special benefit to patients who are encouraged to retain their relationship with Heritage to continue to access and build their personal health database. Patients develop a special relationship with their care coordination team. The patients viewed CYTTA Connect and care coordination activities as a value rather than an intrusion because information and advice generated by the trial were specific to the patient and time sensitive."

"When compared to other remote telemonitoring services available, the CYTTA Connect Ecosystem is clearly the most cost effective, patient friendly system available."

We have designed, built and completed a new technological product that will improve many lives and will vastly improve the way healthcare and any other data is transmitted and utilized. Accordingly, we have determined to be a facilitator of our services to anyone wishing to move data in a new and hitherto unavailable manner. We want to partner and will license any organization that can improve their model with our technology.

Our objective is not to actively enter any specific marketplace, but to license our technology to partners, who have developed the considerable expertise necessary sell, deploy and operate in this sector and others. If you are offering any remote monitoring or data generating technology let us see how we can work together to improve the services you are offering.

Gary Campbell, President

Contact:

Mr. Gary Campbell, President

Direct 702 900 7022

Office 702 253 7499

Website: Cytta.com

[e-mail]

Appendix A Pilot Program Whitepaper

Biometric remote telemonitoring to produce a healthy return on investment, decrease resource utilization, and improve care coordination

By Terry Olson, MD

August 30, 2012

Background

A large full risk, capitated medical group located in Southern California with employed and IPA physicians completed a six (6) month trial to determine if high cost patients not well managed in traditional care coordination programs and traditional healthcare delivery systems can decrease cost of care and improve patient satisfaction through remote telemonitoring using the CYTTA Connect Ecosystem and an intense case management process. Costs were realized in savings from:

Hospital admissions



Emergency Room Visits



Urgent Care Visits



Specialty Visits



Methodology

Twenty-seven (27) patients were identified through claims analysis with frequent use of primary care and specialty visits, Emergency Room visits, Urgent Care visits, Hospital admissions, two (2) or more co-morbidities, and little to no adherence to their current medical treatment plan. After further review, twenty (20) patients were enrolled in to this remote telemonitoring program trial. Resource utilization for the 180 days prior to enrollment in this pilot program was compared to monthly resource utilization during this trial. Patient and Provider satisfaction surveys were sent and interviews were completed with patients, care coordination staff, and physician providers who utilized the telemonitoring technology to determine their satisfaction with the program and case management. Recommendations were formulated at the completion of the trial.

This was a voluntary program which allowed patients to disenroll at any point during the trial. Patients who agreed to participate in the trial completed a 30 minute office orientation session to introduce the telemonitoring products and review the care coordination program. CYTTA provided technical resources, consultation to maintain device performance and all materials and services at no cost. All HIPPA requirements were incorporated into program design and care coordination processes.

Patients participated in the trial from their home after completing the orientation session. Technology performance issues were resolved remotely and within the patient's home for 4 patients. Biometric measurements were available for blood glucose, blood pressure, weight, and pulse oximetry. Results were sent via Bluetooth technology through double FDA approved off the shelf devices and transmitted to the CYTTA Connect dashboard. Access to the dashboard and ability to send care alerts were available to all members of the care coordination team, patients, and designated physicians/family members/caregivers.

Care coordination was provided by nurse and physician services through the existing complex case management employees. Alert programming was established by the Medical Director in association with discussions with primary care provider, specialty providers, and evidence based care guidelines. Alert prompts were sent to nurse care coordinators via email and texts. Nurse coordinators contacted patients in response to alert prompts and on a regular schedule during the trial. Face to face patient interaction with the care coordination team was not required but often transpired during the trial. Patients were able to participate remotely, through face to face interactions in the care coordination clinic, or through face to face home interactions.

Results

Cost of care was reduced by $221,570 for the 20 patients in this 180 day trial. This equates to an average of $11,078 in cost reduction for each patient in the trial. Appendices 1-6 detail pre and post-trial costs of care and sites of utilization. Cost reductions were realized through reduced Emergency Room and Urgent Care visits, reduced specialty visits, and reduced hospital admissions. The reduction in hospital admissions was achieved largely through reduced readmissions. The table below summarizes utilization for trial members. The use of CYTTA Connect Ecosystem during this trial reduced utilization in the initial 90 days, but produced even more dramatic reductions in the second 90 day period. This supports the belief that patients began to learn how to better self-manage their conditions as they became familiar with the program and their care coordinators. The average reimbursement for a hospital inpatient DRG was estimated at $22,000; Emergency room visits average $1,200.00/visit; specialty physician visits average $125/visit while urgent care visits average $90/visit.

Special note is made regarding 3 unavoidable hospital admissions with prolonged inpatient stays.

1. A member with no prior history of upper gastrointestinal bleeding developed abrupt hematemesis in addition to their diagnosis of end stage idiopathic pulmonary fibrosis. The member was admitted and spent 9 days in the hospital with a bleeding gastric ulcer.

2. A dialysis member with narcotic dependency, diabetes, and advanced degenerative spinal disease suffered a traumatic neck injury resulting in a 69 day stay and quadriplegia.

3. A member with idiopathic cardiomyopathy developed left ventricular assist device infection requiring hospital admission, LVAD removal, placement of an intra-aortic balloon pump and continued inpatient stay until a heart was found and heart transplantation completed. This resulted in a 73 day inpatient stay.

Summary of Trial results

----------------------------------------------------------------------------
Last 90 days
Pre-trial Post-trial of trial Change Cost Savings
----------------------------------------------------------------------------
Admits 28 17 3 9 $198,000
----------------------------------------------------------------------------
Readmits 12 5 0 7 $140,000
----------------------------------------------------------------------------
Bed Days 90 143 80 (53)
----------------------------------------------------------------------------
ER Visits 44 26 4 18 $21,600
----------------------------------------------------------------------------
UC Visits 12 4 1 8 $720
----------------------------------------------------------------------------
Specialists 102 92 36 10 $1,250
----------------------------------------------------------------------------
PCP 92 78 18 14 Capitated
----------------------------------------------------------------------------
Total Cost
Savings $221,570
----------------------------------------------------------------------------
Cost Savings per
Member over 6
months $11,078
----------------------------------------------------------------------------
Cost savings per
Member per
month $1,846
----------------------------------------------------------------------------

Value creation was identified in 4 areas during the trial:

1. Improved patient engagement and ability to self-manage care

2. Improved provider engagement

3. Patient loyalty

4. Improved care coordinating performance

Enrollment criteria identified patients who struggled to manage their health despite best available resources in our current healthcare environment. This trial demonstrated these patients were not able to self-manage their care. The patients visited the hospital, emergency room, and physician offices in search of a solution to their healthcare needs. Those efforts were previously costly and ineffective.

Trial participation and the use of the CYTTA Connect Ecosystem discovered these patients were rarely engaged or knowledgeable in self-management of their healthcare needs. Repeated use of available resources did little to address this deficit. The CYTTA Connect Ecosystem in association with care coordination enabled the patient and team to identify and address barriers to self-management and adherence to evidence based guidelines. Barriers included knowledge deficits, outpatient monitoring deficits, absence of prompt and effective care plan revision when biometric guidelines were not met, and social factors.

Physician providers who participated in the trial voiced tremendous support for biometric remote telemonitoring. Physicians noted many of the previously reported home biometric monitoring was inaccurate, fabricated, or absent. Patients, physicians, and care coordination team members confirmed that biometric results were rapidly available and accurate. Sampling error or erroneous results reporting was not a problem. Physicians and care coordination team members noted their level of engagement and effectiveness was tremendously improved with accurate, timely, and frequent reports of blood pressure, blood sugar, weight, and oxygenation status.

As patients participated in the trial and received customized care coordination they became more engaged in their healthcare management and frequently voiced the admiration for effective service delivery. Patients commonly noted their neighbors, family members, church members, and others were amazed by the service delivered and wanted access to the trial. Patients noted they were not only more satisfied with the service delivered by the medical group but also noted they would never consider switching health plans or medical groups because they feared they would lose access to the CYTTA Connect Ecosystem and care coordination.

The complex care coordination team noted their ability to effectively manage and their personal satisfaction was tremendously increased through trial participation. The team noted the absence of playing telephone tag with patients and the absence of erroneous home biometric self-reports by patients. The team noted that the CYTTA Connect alerts required an active care plan which was clearly understood by the patient, the managing physicians, and the care coordination team. This was clearly absent prior to this trial. In addition, standing orders were required to promptly address care alerts so that blood pressure, blood sugars, weight, and oxygenation guidelines were met. The trial demonstrated the absence of effective, real time care plan and medication revision in existing care programs. The absence of timely care plan revision in addition to unclear care plans produced significant care team dissatisfaction. This trial and CYTTA Connect removed that dissatisfaction while improving care team performance.

Conclusions

This trial demonstrated the ability to significantly reduce costs for high risk patients through use of the CYTTA Connect Ecosystem. The trial demonstrated the ability to quickly achieve cost savings, decrease resource utilization, improve care coordination, and increase adherence to evidence based guidelines. Adherence to evidence based guidelines is increasingly important as CMS 5 STAR ratings garner importance.

Care costs were reduced on average by $11,078 for each trial participant. This trial did not specifically address long term cost of care. However, these patients were selected for the inabilities of the existing healthcare system and care coordination programs to cost effectively address their short or long term healthcare needs. One trial participant noted he realized more value and benefit in 2 months of trial participation compared to his previous 17 months of participation in the best available care coordination services. A quite handsome return on investment is present if the care coordination system is priced at less than $2,000 per year.

This trial also demonstrated that home biometric monitoring using the CYTTA Connect Ecosystem can be easily introduced, dispensed and utilized in the home setting. Care team training was easily completed. CYTTA Connect was easy for patients and care coordinators to learn and effectively use. Technical troubleshooting was prompt and effective.

Improved patient engagement and ability to self-manage care will become increasingly important and require new resource allocation because CMS will soon require Stage II Readiness participation. Through repeated collection and review of biometric data patients learn how to titrate medications and adjust behaviors to achieve target goals which is a cornerstone of CMS 5 STAR performance and CMS Stage II Readiness. Patients and the care coordination team are prompted by alerts to evaluate and to intervene in real time. This produces a patient who is more engaged and prospectively aware of how they must modify behaviors and medications to meet target metrics through self-management. Additionally, improved achievement of target metrics produces significant provider and care team satisfaction. Efforts of both become both more effective and more efficient.

Effective use of the CYTTA Connect Ecosystem requires the managing physicians to develop and communicate care plans and standing orders to adjust medications to achieve target goal. Too often the goals of care and associated care plans including medication administration are poorly communicated or not present. Patients travel through various sites of service and levels of care without a clear understanding of the expected behaviors and medication usage to be executed in the home setting. CYTTA Connect in conjunction with care coordination resolves this deficit and allows for care plan and medication revision as the patient disease processes change in the home environment. Through repeated measurement and with focused care coordination the patient learns how to better manage their health care needs. This produces a patient who is more engaged and prospectively aware of how they must modify behaviors and medications to meet target metrics. This also produces a more satisfied patient, physician, and care coordination team.

This trial discovered patients view CYTTA Connect and remote telemonitoring as a special benefit to patients who are encouraged to retain their relationship with Heritage to continue to access and build their personal health database. Patients develop a special relationship with their care coordination team. The patients viewed CYTTA Connect and care coordination activities as a value rather than an intrusion because information and advice generated by the trial were specific to the patient and time sensitive.

This trial enabled physicians and care coordinators to more effectively manage a larger number of patients. Current care coordination ratios can be expanded by 20% using biometric remote telemonitoring through reduced telephone tag and elimination of unfocused, subjective, generic discussions with patients. Instead specific biometric data, medication usage, review of the active care plan, and comparison to target metrics produces a focused discussion. Patients and care coordinators are taught through rapid cycle improvement to Plan, Do, Study, and ACT. Barriers to successful self-management are identified and addressed. Patients now learn how to revise and update their care management in the home setting rather than a physician office, emergency or hospital room followed by an attempt to translate and implement the care plan in their home setting upon discharge. Patient contacts have become value oriented with immediate return on investment to the care coordinators and patient.

Next Steps

We believe the success of this remote telemonitoring program on managing high risk patients can be replicated and offered to forward thinking, at risk healthcare organizations. The telemonitoring success requires careful patient selection, structured patient enrollment and focused care coordination which have been developed and tested. Ongoing success requires structured patient assessment, patient and provider engagement, alert parameter selection with provider input with standing orders in response to alerts. CYTTA and MHIMS provides coordination between the providers and systems to introduce and educate on the use of the telemonitoring program to reduce ER and hospitalizations usage with increased patient involvement and increased positive outcomes in health self-management for high need members. We can identify high cost members and offer this program to non-high cost patients who are discharging from the hospital but at high risk for readmission due to their inability to effectively self-manage their care in the home setting.

When compared to other remote telemonitoring services available, the CYTTA Connect Ecosystem is clearly the most cost effective, patient friendly system available.

Although the pilot study was completed, CYTTA continued to provide their products which demonstrated additional cost savings and dramatically reduced utilization past the initial 180 day pilot.

Contact:

Mr. Gary Campbell

President

Direct 702 900 7022

Office 702 253 7499

Website: Cytta.com

[e-mail]

[Nikkitawin]

Company Filings: http://www.otcmarkets.com/stock/CYCA/filings

News: http://www.otcmarkets.com/stock/CYCA/news

Webseite: http://www.cytta.com

Trade Activity: http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p…